RenovoRx Announces That The Northwell Health Cancer Institute In New Hyde Park, NY Is Enrolling Patients With Locally Advanced Pancreatic Cancer In The Co's Ongoing Phase III TiGeR-PaC Clinical Trial; NHCI Joins Esteemed Clinical Sites Throughout The U.S. Participating In The Study
The Northwell Health Cancer Institute is the Most Recent Clinical Site to Join the TIGeR-PaC Study, and RenovoRx Aims to Reach Full Patient Enrollment in the First Half of 2025
Phase III Clinical Trial is Evaluating the TAMP (Trans-Arterial Micro-Perfusion) Therapy Platform for the Treatment of Locally Advanced Pancreatic Cancer
LOS ALTOS, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life sciences company developing novel targeted oncology therapies and offering RenovoCath, a novel, FDA-cleared local drug-delivery platform, announced today that the Northwell Health Cancer Institute ("NHCI") in New Hyde Park, NY is enrolling patients with locally advanced pancreatic cancer (LAPC) in the Company's ongoing pivotal Phase III TIGeR-PaC clinical trial. NHCI joins esteemed clinical sites throughout the United States participating in the study.
